Comparison of Healthcare Resource Utilization (HRU) and Costs Related to Pleural Effusion (PE) Between Patients Newly Diagnosed with Chronic Myeloid Leukemia (CML) Treated with Dasatinib or Nilotinib as First-Line Therapy in the United Stat ...
Abstract
Authors
K Seiter D Latremouille-Viau A Guerin B Ndife K Habucky GJ Joseph I Pivneva P Gagnon-Sanschagrin DH Tang